Real-World Clinical Effectiveness and Safety of Vedolizumab and Ustekinumab in Biologic-Naive Patients With Crohn’s Disease By Disease Location
Effectiveness, safety, and health care resource utilization outcomes over 36 months were similar between treatment cohorts regardless of baseline disease location. The number of patients requiring CD-related surgeries was low. Both vedolizumab and ustekinumab can be used as first-line biologics in patients with CD, regardless of disease location.
Authors
- Pravin Kamble (ORCID: https://orcid.org/0000-0003-0395-4494)
- Zeinab Farhat (ORCID: https://orcid.org/0000-0001-9349-8431)
- Britt Christensen (ORCID: https://orcid.org/0000-0002-8746-4275)
- Marc Ferrante (ORCID: https://orcid.org/0000-0003-1492-0716)
- Lauren Gianchetti (ORCID: https://orcid.org/0000-0002-9665-6076)
- Michael M. Scharl (ORCID: https://orcid.org/0000-0002-6729-1469)
- Brian Bressler (ORCID: https://orcid.org/0000-0003-4740-8209)
- Neil R. Brett (ORCID: https://orcid.org/0000-0002-6175-2535)
- Shashi Adsul (ORCID: https://orcid.org/0000-0002-0593-1088)
- Celine Gisler
Institutions
- The Royal Melbourne Hospital (AU)
- The University of Melbourne (AU)
- University of Zurich (CH)
- St. Paul's Hospital (CA)
- Thermo Fisher Scientific (Canada) (CA)
- University Hospital of Zurich (CH)
- Takeda (United States) (US)
- Thermo Fisher Scientific (United States) (US)
- KU Leuven (BE)
Publication Details
- Journal
- Journal of Clinical Gastroenterology
- Published
- 2025-06-20
- DOI
- https://doi.org/10.1097/mcg.0000000000002186
- Citations
- 1
- Primary Topic
- Inflammatory Bowel Disease
- Type
- article
- Field-Weighted Citation Impact
- 1.82